Christopher Murphy is chief operating officer at Brammer Bio. Chris has more than 30 years of experience in biopharmaceutical manufacturing, process development, plant operations, and quality system implementation. Prior to joining Brammer Bio, Chris served as general manager for the Sanofi-Genzyme Allston Landing site overseeing operations and leading an integrated remediation program associated with the consent decree. In addition to his role in Allston, Chris was Site Head for Genzyme’s gene therapy operation in San Diego, CA and led commercial manufacturing of recombinant protein products in Framingham, MA. Prior to joining Genzyme, Chris was responsible for US contract manufacturing at Bioreliance (Rockville, MD), focused on viral vector manufacturing and cell banking. Chris began his career at American Cyanamid/Wyeth (now Pfizer) in Pearl River, NY. In his 10 years with the company, he held positions in quality control, viral vaccine development, and drug substance manufacturing. He earned his M.Sc. in biochemistry at New York Medical College, and his B.Sc. in biology at Rutgers University.